Building Blocks

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

Versatile small molecule scaffold

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>3-Chloro-N-methyl-2-nitroaniline is an antibiotic that belongs to the group of quinolone antibiotics. It has a broad spectrum against Gram-positive and Gram-negative bacteria, including methicillin resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. 3-Chloro-N-methyl-2-nitroaniline binds to bacterial DNA gyrase and topoisomerase IV, as well as human DNA gyrase and topoisomerase II, inhibiting their activity. This leads to cell death by interfering with the production of proteins vital for cell division. The optimal parameters for this drug have been found using isothermal titration calorimetry on the enzyme gyrase in the presence of different concentrations of 3CMA. Pharmacological targets for this drug include DNA gyrase and topoisomerase IV.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>2-Chloro-1-[5-(3,4-dimethoxyphenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]ethan-1-one is a natural product that falls under the category of Research Chemicals. It is a pyrimidone compound that has shown potential as an anticoronaviral agent. This compound is known for its ability to inhibit neuronal uptake and has been found to be oxidized in the presence of certain enzymes. The chlorinated structure of this compound contributes to its unique properties and potential applications. Additionally, it has been observed to interact with serotonin receptors and exhibit vinyl-like characteristics. Overall, 2-Chloro-1-[5-(3,4-dimethoxyphenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]ethan-</p>

<p>Bicyclo[4.1.0]heptan-7-ylmethanol is a hydride inhibitor of lactate dehydrogenase, which is an enzyme that catalyzes the conversion of pyruvate to lactate in the liver. Bicyclo[4.1.0]heptan-7-ylmethanol has inhibitory properties against aldehyde dehydrogenase and alcohol dehydrogenase, which are enzymes involved in the metabolism of aldehydes and alcohols respectively. This substance also inhibits mitochondrial monoamine oxidase (MAO), which is an enzyme that breaks down neurotransmitters such as dopamine, norepinephrine, and serotonin. Bicyclo[4.1.0]heptan-7-ylmethanol can be used to inhibit the function of MAO in order to increase levels of these neurotransmitters in the brain, which may be helpful for conditions like depression or Parkinson</p>

<p>1-Benzothiophene-6-carboxylic acid is a nicotinic acetylcholine receptor agonist that has been shown to have high oral bioavailability and efficacy in vivo. It binds to the α7 nicotinic acetylcholine receptor and activates the receptor, leading to increased neurotransmitter release. 1-Benzothiophene-6-carboxylic acid has been shown to be effective in vivo in models of neuropathic pain and Parkinson's disease. This drug also has a low affinity for other receptors, such as muscarinic acetylcholine receptors, which reduces the chance of adverse effects.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>